Основная статистика
| CIK | 1799448 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Aligos Therapeutics, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 6, 2025 |
Form of Change of Control Severance Agreement Exhibit 10.3 ALIGOS THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between [Insert executive name] (“Executive”) and Aligos Therapeutics, Inc. (the “Company”), effective as of [Insert Effective Date – e.g., date of hire of VP or date of promotion to VP] (the “Effective Date”). Background |
|
| August 6, 2025 |
As filed with the Securities and Exchange Commission on August 6, 2025 S-8 As filed with the Securities and Exchange Commission on August 6, 2025 Registration No. |
|
| August 6, 2025 |
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) - Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 6, 2025 |
Calculation of Filing Fee Tables S-8 Aligos Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, $0.0001 par value per share Other 1,000,000 $ 7.49 $ 7,490,000.00 0.0001531 $ 1,146.72 Total |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39617 Aligos Therapeutics, Inc. |
|
| June 26, 2025 |
Amendment to 2020 Incentive Award Plan. Exhibit 10.1 AMENDMENT TO ALIGOS THERAPEUTICS, INC. 2020 INCENTIVE AWARD PLAN THIS AMENDMENT (this “Amendment”) to the Aligos Therapeutics, Inc. 2020 Incentive Award Plan, as amended (the “Plan”), is made and adopted by the Board of Directors (the “Board”) of Aligos Therapeutics, Inc., a Delaware corporation (the “Company”), subject to, and effective upon, the approval of the Company’s stockholder |
|
| June 26, 2025 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ALIGOS THERAPEUTICS, INC. Aligos Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, hereby certifies as follows: ONE: The name of this corporation is Aligos Therapeutics, Inc. The Co |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commission |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39617 Aligos Therapeutics, Inc. |
|
| May 6, 2025 |
Non-Employee Director Compensation Program Exhibit 10.1 ALIGOS THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (As Amended Effective: April 16, 2025) This Aligos Therapeutics, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2020 Incentive Award Plan (the “Plan”) and has been amended as of April 16, 2025 (the “Effective Date”). Capitalized terms not otherwis |
|
| May 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 6, 2025 |
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) - Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress a |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| April 28, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 16, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| April 3, 2025 |
6,245,475 Shares Common Stock Offered by the Selling Securityholders Table of Contents As Filed Pursuant to Rule 424(b)(3) Registration No. 333-286168 PROSPECTUS 6,245,475 Shares Common Stock Offered by the Selling Securityholders This prospectus relates to the resale from time to time of up to an aggregate of 6,245,475 shares of our common stock, $0.0001 par value per share, by the selling securityholders identified in this prospectus (collectively with any donees |
|
| April 1, 2025 |
Aligos Therapeutics, Inc. One Corporate Dr., 2nd Floor South San Francisco, CA 94080 Aligos Therapeutics, Inc. One Corporate Dr., 2nd Floor South San Francisco, CA 94080 April 1, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Alan Campbell Re: Aligos Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-286168) Ladies and Gentlemen: In accordance with R |
|
| March 27, 2025 |
As filed with the Securities and Exchange Commission on March 27, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on March 27, 2025 Registration No. |
|
| March 27, 2025 |
Exhibit 107.1 Calculation of Filing Fee Table Registration Statement on Form S-3 (Form Type) Aligos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 10, 2025 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Aligos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $ |
|
| March 10, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 10, 2025 |
Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following summary describes the capital stock of Aligos Therapeutics, Inc. (the “Company,” “we,” “us” and “our”) and the material provisions of our amended and restated certificate of incorporation, our amended and restated bylaws and of the General Corporation Law of the State of Delaware. Because the following is only a summary, it does not contain al |
|
| March 10, 2025 |
Exhibit 19.1 Aligos Therapeutics, Inc. Insider Trading Compliance Policy and Procedures Effective October 31, 2023 Federal and state laws prohibit trading in the securities of a company while in possession of material nonpublic information regarding that company and in breach of a duty of trust or confidence. These laws also prohibit anyone who is aware of material nonpublic information from provi |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39617 Aligos Therape |
|
| March 10, 2025 |
Exhibit 10.18 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 13, 2025, is entered into by and among Aligos Therapeutics, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized ter |
|
| March 10, 2025 |
Exhibit 10.19 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made as of February 13, 2025 by and between Aligos Therapeutics, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (each, an “Investor”, and collectively, the “Investors”). Unless otherwise defined herein, capitaliz |
|
| March 10, 2025 |
EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) - Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent bu |
|
| March 10, 2025 |
Letter Agreement, by and among the Company and the investors party thereto. Exhibit 10.20 Aligos Therapeutics, Inc. One Corporate Drive, 2ndFloor South San Francisco, California February 13, 2025 Baker Brothers Life Sciences, L.P. 667, L.P. ########## Re: Aligos Therapeutics, Inc. Reference is made to that certain Securities Purchase Agreement, dated as of February 11, 2025, by and among Aligos Therapeutics, Inc. (the “Company”), Baker Bros. Life Sciences, L.P. and 667, L |
|
| February 12, 2025 |
EX-99.1 Exhibit 99.1 Aligos Therapeutics Announces $105 Million Private Placement Financing Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study Funding expected to extend cash runway into the second half of 2026 SOUTH SAN FRANCISCO, Calif., February 12, 2025 (GLOBE NEWSWIRE) – Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biotechnology com |
|
| February 12, 2025 |
Form of Registration Rights Agreement. EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February [], 2025, is entered into by and among Aligos Therapeutics, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitali |
|
| February 12, 2025 |
Exhibit 4.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES, OR IN ANY OTHER JURISDICTION. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED, SOLD, TRANSFERRED OR ASSIGN |
|
| February 12, 2025 |
Form of Lead Investor Registration Rights Agreement. EX-10.3 Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made as of February [•], 2025 by and between Aligos Therapeutics, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (each, an “Investor”, and collectively, the “Investors”). Unless otherwise defined herein, c |
|
| February 12, 2025 |
EX-10.4 Exhibit 10.4 Aligos Therapeutics, Inc. One Corporate Drive, 2nd Floor South San Francisco, California February [●], 2025 Baker Brothers Life Sciences, L.P. 667, L.P. ########### Re: Aligos Therapeutics, Inc. Reference is made to that certain Securities Purchase Agreement, dated as of February [●], 2025, by and among Aligos Therapeutics, Inc. (the “Company”), Baker Bros. Life Sciences, L.P. |
|
| February 12, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of February 11, 2025, by and among Aligos Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and delive |
|
| February 12, 2025 |
Form of 2025 Pre-Funded Warrant. EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED, SOLD, TRANSFERRED OR |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commis |
|
| February 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2025 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commiss |
|
| November 14, 2024 |
SC 13G/A 1 ea022116102-13ga1viv8aligos.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 01626L204 (CUSIP Number) September 30, 2024 (Date of Event which Requir |
|
| November 14, 2024 |
ALGS / Aligos Therapeutics, Inc. / Alyeska Investment Group, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 14, 2024 |
ALGS / Aligos Therapeutics, Inc. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 01626L204 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| November 14, 2024 |
SC 13G/A 1 p24-3177sc13ga.htm ALIGOS THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Aligos Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 01626L204 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of Thi |
|
| November 14, 2024 |
Aligos Therapeutics, Inc. One Corporate Dr., 2nd Floor South San Francisco, CA 94080 CORRESP Aligos Therapeutics, Inc. One Corporate Dr., 2nd Floor South San Francisco, CA 94080 November 14, 2024 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Daniel Crawford Re: Aligos Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-283041) Ladies and Gent |
|
| November 14, 2024 |
EX-99.1 2 ea022116102ex99-1aligos.htm JOINT FILING STATEMENT Exhibit 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A shall be filed on behalf of each of the undersigned without the necessity of filing additional joint |
|
| November 14, 2024 |
ALGS / Aligos Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 12, 2024 |
SC 13G 1 p24-3089sc13g.htm ALIGOS THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aligos Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value, $0.0001 per share (Title of Class of Securities) 01626L204 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Sta |
|
| November 12, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p24-3089exhibit99.htm JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K) EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without |
|
| November 6, 2024 |
Exhibit 4.6 Aligos Therapeutics, Inc. INDENTURE Dated as of [], 20[] [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 6 Section 2.1. Issuable in Series 6 Section 2.2. Est |
|
| November 6, 2024 |
September 4, 2024 ALIGOS THERAPEUTICS, INC. Hardean Achneck [email protected] RE: Employment Terms Dear Hardean: As you have indicated an interest in joining Aligos Therapeutics, Inc., a Delaware corporation (the “Company”), I am pleased to offer you full-time employment in the regular exempt position of Executive Vice President, Chief Medical Officer effective as of your initial date of employme |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 6, 2024 |
As filed with the Securities and Exchange Commission on November 6, 2024 As filed with the Securities and Exchange Commission on November 6, 2024 Registration No. |
|
| November 6, 2024 |
Non-Employee Director Compensation Policy Exhibit 10.3 ALIGOS THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (As Amended Effective: October 16, 2024) This Aligos Therapeutics, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2020 Incentive Award Plan (the “Plan”) and has been amended as of October 16, 2024 (the “Effective Date”). Capitalized terms not othe |
|
| November 6, 2024 |
2024 Employment Inducement Award Plan. Exhibit 10.1(a) Aligos Therapeutics, Inc. 2024 EMPLOYMENT INDUCEMENT AWARD PLAN ARTICLE I. Purpose The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate employees who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. ARTICLE II. Definitions As used in the Plan, the following words and phr |
|
| November 6, 2024 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Aligos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 pa |
|
| November 6, 2024 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-3 (Form Type) Aligos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration |
|
| November 6, 2024 |
Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement. Exhibit 10.1(c) Aligos Therapeutics, Inc. 2024 EMPLOYMENT INDUCEMENT AWARD PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Aligos Therapeutics, Inc., a Delaware corporation (the “Company”), pursuant to its 2024 Employment Inducement Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”), an award of restricted stock units (“Restricted Stoc |
|
| November 6, 2024 |
Form of Common Stock Certificate. Exhibit 4.2 SEE REVERSE FOR IMPORTANT NOTICE REGARDING OWNERSHIP AND TRANSFER RESTRICTIONS AND CERTAIN OTHER INFORMATION ALIGOS THERAPEUTICS INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE COMMON STOCK CUSIP 01626L 20 4 SEE REVERSE FOR CERTAIN DEFINITIONS THIS CERTIFIES THAT SPECIMEN IS THE OWNER OF FULLY PAID AND NON-ASSESSABLE SHARES OF THE COMMON STOCK, $.0001 PAR VALUE, OF ALIGOS THERAPEU |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39617 Aligos Therapeutics, Inc. |
|
| November 6, 2024 |
Form of Common Stock Certificate. 0000001 SPECIMEN SEE REVERSE FOR IMPORTANT NOTICE REGARDING OWNERSHIP AND TRANSFER RESTRICTIONS AND CERTAIN OTHER INFORMA TION FULLY PAID AND NON-ASSESSABLE SHARES OF THE COMMON STOCK, $. |
|
| November 6, 2024 |
Aligos Therapeutics, Inc. September 4, 2024 Dear Hardean: As you have indicated an interest in joining Aligos Therapeutics, Inc., a Delaware corporation (the “Company”), I am pleased to offer you full-time employment in the regular exempt position of Executive Vice President, Chief Medical Officer effective as of your initial date of employment, which is currently anticipated to be on or about Sep |
|
| November 6, 2024 |
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) - Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progr |
|
| November 6, 2024 |
As filed with the Securities and Exchange Commission on November 6, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on November 6, 2024 Registration No. |
|
| November 6, 2024 |
Form of Stock Option Grant Notice and Stock Option Agreement. Exhibit 10.1(b) Aligos Therapeutics, Inc. 2024 Employment Inducement AWARD PLAN STOCK OPTION GRANT NOTICE Aligos Therapeutics, Inc., a Delaware corporation (the “Company”), pursuant to its 2024 Employment Inducement Award Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), an option to purchase the number of shares of the Company’s Comm |
|
| September 12, 2024 |
ALGS / Aligos Therapeutics, Inc. / ICS OPPORTUNITIES II LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ALIGOS THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 01626L204 (CUSIP Number) SEPTEMBER 9, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant t |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commis |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commissi |
|
| August 19, 2024 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ALIGOS THERAPEUTICS, INC. Aligos Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, hereby certifies as follows: ONE: The name of this corporation is Aligos Therapeutics, Inc., the C |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commissio |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39617 Aligos Therapeutics, Inc. |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 6, 2024 |
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) - Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business pro |
|
| August 6, 2024 |
Non-Employee Director Compensation Policy. EX-10.1 ALIGOS THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (As Amended Effective: July 24, 2024) This Aligos Therapeutics, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2020 Incentive Award Plan (the “Plan”) and has been amended as of April 17, 2024 (the “Effective Date”). Capitalized terms not otherwise defi |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commission |
|
| June 28, 2024 |
Amendment to 2020 Incentive Award Plan. Exhibit 10.1 AMENDMENT TO THE ALIGOS THERAPEUTICS, INC. 2020 INCENTIVE AWARD PLAN Effective June 27, 2024 This Amendment (“Amendment”) to the Aligos Therapeutics, Inc. 2020 Incentive Award Plan (as amended, the “Plan”) is effective as of the date first set forth above. 1. Section 2.28 of the Plan is hereby amended and restated in its entirety to read as follows: ““Overall Share Limit” means the su |
|
| June 28, 2024 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ALIGOS THERAPEUTICS, INC. Aligos Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, hereby certifies as follows: ONE: The name of this corporation is Aligos Therapeutics, Inc. The Co |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commission |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commission |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commission F |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39617 Aligos Therapeutics, Inc. |
|
| May 7, 2024 |
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) - Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progr |
|
| April 29, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| April 16, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| March 12, 2024 |
Policy relating to Recovery of Erroneously Awarded Compensation Exhibit 97.1 ALIGOS THERAPEUTICS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Aligos Therapeutics, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined in the text of this Policy are defined in Section 11 o |
|
| March 12, 2024 |
As filed with the Securities and Exchange Commission on March 12, 2024 As filed with the Securities and Exchange Commission on March 12, 2024 Registration No. |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39617 Aligos Therape |
|
| March 12, 2024 |
Exhibit 10.17 ALIGOS THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Lesley Ann Calhoun (“Executive”) and Aligos Therapeutics, Inc. (the “Company”), effective as of December 1, 2020 (the “Effective Date”). Background A. The Board of Directors of the Company (the “Board”) recognizes |
|
| March 12, 2024 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Aligos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 |
|
| March 12, 2024 |
EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results SOUTH SAN FRANCISCO, Calif., March 12, 2024 (GLOBE NEWSWIRE) - Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported rece |
|
| March 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 12, 2024 |
Separation and release agreement with Leonid Beigelman Exhibit 10.18 SEPARATION AND GENERAL RELEASE AGREEMENT THIS SEPARATION AND GENERAL RELEASE AGREEMENT (this “Agreement”) is made and entered into as of the Effective Date, defined in Section 6(e) below, by and between, Leonid Beigelman, Ph.D., an individual (the “Employee”), and Aligos Therapeutics, Inc., a Delaware Corporation (the “Company”) (collectively the “Parties,” and each a “Party”). WHERE |
|
| March 12, 2024 |
Exhibit 10.16 ALIGOS THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Matthew McClure (“Executive”) and Aligos Therapeutics, Inc. (the “Company”), effective as of December 1, 2020 (the “Effective Date”). Background A. The Board of Directors of the Company (the “Board”) recognizes th |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commis |
|
| February 28, 2024 |
SC TO-I/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) ALIGOS THERAPEUTICS, INC. (Name of Subject Company (Issuer)) ALIGOS THERAPEUTICS, INC. (Name of Filing Person (Offeror)) Options To Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Sec |
|
| February 14, 2024 |
ALGS / Aligos Therapeutics, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 algs13ga2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 01626L105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| February 14, 2024 |
SC 13G/A 1 p24-0560sc13ga.htm ALIGOS THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Aligos Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 01626L105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This |
|
| February 14, 2024 |
ALGS / Aligos Therapeutics, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 z110241sc13ga2.htm AMENDMENT NO. 2 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 01626L105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check t |
|
| February 14, 2024 |
ALGS / Aligos Therapeutics, Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SC 13G/A 1 tm242424d9sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 01626L105 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appr |
|
| February 14, 2024 |
ALGS / Aligos Therapeutics, Inc. / Alyeska Investment Group, L.P. Passive Investment SC 13G 1 alyeska-algs123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 01626L105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 14, 2024 |
ALGS / Aligos Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 8, 2024 |
ALGS / Aligos Therapeutics, Inc. / Versant Venture Capital VI, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 01626L 10 5 (CUSIP Number) V |
|
| January 30, 2024 |
Exhibit (a)(1)(iv) FORM OF ANNOUNCEMENT EMAIL TO ELIGIBLE PARTICIPANTS TO: [Participant] FROM: info@mail. |
|
| January 30, 2024 |
Exhibit (a)(1)(vii) FORM OF FINAL REMINDER EMAIL COMMUNICATION TO: [ ] FROM: info@mail. |
|
| January 30, 2024 |
Option Exchange Frequently Asked Questions Exhibit (a)(1)(ix) OPTION EXCHANGE FREQUENTLY ASKED QUESTIONS The following are answers to some of the questions that you may have about the Option Exchange. |
|
| January 30, 2024 |
Email to all eligible participants from Lawrence M. Blatt, Ph.D. Exhibit (a)(1)(ii) EMAIL TO ALL ELIGIBLE PARTICIPANTS FROM LAWRENCE M. BLATT, PH.D., ALIGOS’ CHIEF EXECUTIVE OFFICER, DATED JANUARY 30, 2024 To: Eligible Aligos Participants From: [email protected], on behalf of Lawrence M. Blatt, Ph.D., Chief Executive Officer Date: January 30, 2024 Re: Aligos’ Option Exchange Program We are pleased to announce that Aligos is launching an important compen |
|
| January 30, 2024 |
Form of Email Confirming Receipt of Election Exhibit (a)(1)(vi) FORM OF EMAIL CONFIRMING RECEIPT OF ELECTION TO: [ ] FROM: info@mail. |
|
| January 30, 2024 |
Form of Reminder Email Communication Exhibit (a)(1)(v) FORM OF REMINDER EMAIL COMMUNICATION TO: [ ] FROM: info@mail. |
|
| January 30, 2024 |
Exhibit (a)(1)(iii) ALIGOS THERAPEUTICS, INC. TERMS OF ELECTION BY PARTICIPATING, YOU AGREE TO ALL TERMS OF THE OFFER AS SET FORTH IN THE OFFER TO EXCHANGE CERTAIN OUTSTANDING OPTIONS TO PURCHASE COMMON STOCK FOR A NUMBER OF REPLACEMENT OPTIONS, DATED JANUARY 30, 2024 (AS IT MAY BE AMENDED FROM TIME TO TIME, THE “OFFER TO EXCHANGE”). If you would like to participate in this Offer, please indicate |
|
| January 30, 2024 |
Screen Shots of Option Exchange Website Exhibit (a)(1)(viii) Welcome Election Form Value Calculator Resources Form of Terms of Election Form of Announcement Email Form of Reminder Email Form of Email Confirming Receipt Form of Final Reminder Email Option Exchange FAQs The PDF documents above require Adobe Acrobat Reader If necessary you can download it from Adobe. |
|
| January 30, 2024 |
Offer to Exchange Certain Outstanding Options to Purchase Common Stock, dated January 30, 2024 Exhibit (a)(1)(i) ALIGOS THERAPEUTICS, INC. OFFER TO EXCHANGE CERTAIN OUTSTANDING OPTIONS TO PURCHASE SHARES OF COMMON STOCK FOR A NUMBER OF REPLACEMENT OPTIONS SUMMARY TERM SHEET – OVERVIEW THIS OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 11:59 P.M. EASTERN TIME ON FEBRUARY 27, 2024 UNLESS THIS OFFER IS EXTENDED Aligos Therapeutics, Inc. which is sometimes referred to herein as the “Company,” “Aligos,” |
|
| January 30, 2024 |
Exhibit 107 Calculation of Filing Fee Table SC TO-I (Form Type) Aligos Therapeutics, Inc. |
|
| January 30, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ALIGOS THERAPEUTICS, INC. (Name of Subject Company (Issuer)) ALIGOS THERAPEUTICS, INC. (Name of Filing Person (Offeror)) Options To Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 01626L105 (CUSIP Nu |
|
| January 30, 2024 |
Option Exchange Presentation for Eligible Participants Exhibit (a)(1)(x) Option Exchange Program Education & Information Session January 30, 2024 Disclaimer The statements in this presentation concerning the Option Exchange, Eligible Options, the equity incentive plans, and the replacement Options are summaries and are not complete descriptions thereof. |
|
| January 25, 2024 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 Aligos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39617 82-4724808 (State or Other Jurisdiction of Incorporation) |
|
| January 25, 2024 |
Exhibit 99.1 Hello Everyone, At Aligos, we regularly evaluate our rewards and compensation approach to ensure our employee compensation is competitive, to reward you for your work and to show you how valued you are for your work. We believe that focus on attracting and retaining top talent is the best way to ensure we build a lasting company. An important part of this focus is our equity program, |
|
| January 25, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 Aligos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39617 82-4724808 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 28, 2023 |
168,725,925 Shares Common Stock Offered by the Selling Securityholders Table of Contents As Filed Pursuant to Rule 424(b)(3) Registration No. 333-275636 PROSPECTUS 168,725,925 Shares Common Stock Offered by the Selling Securityholders This prospectus relates to the resale from time to time of up to an aggregate of 168,725,925 shares of our common stock, $0.0001 par value per share, by the selling securityholders identified in this prospectus (collectively with any do |
|
| November 22, 2023 |
Aligos Therapeutics, Inc. One Corporate Dr., 2nd Floor South San Francisco, CA 94080 Aligos Therapeutics, Inc. One Corporate Dr., 2nd Floor South San Francisco, CA 94080 November 22, 2023 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Aligos Therapeutics, Inc. Registration Statement on Form S-3 Filed November 17, 2023 Registration No. 333-2756 |
|
| November 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commis |
|
| November 17, 2023 |
As filed with the Securities and Exchange Commission on November 17, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on November 17, 2023 Registration No. |
|
| November 17, 2023 |
Exhibit 107.1 Calculation of Filing Fee Table Registration Statement on Form S-3 (Form Type) Aligos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commiss |
|
| November 7, 2023 |
ALGS / Aligos Therapeutics Inc / ROCHE FINANCE LTD - SC 13G/A Passive Investment SC 13G/A 1 tm2329765d2sc13ga.htm SC 13G/A CUSIP No. 01626L105 SCHEDULE 13G/A Page 1 of 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 01626L105 (CUSIP Number) October 25, 2023 (Date o |
|
| November 6, 2023 |
ALGS / Aligos Therapeutics Inc / BLATT LAWRENCE - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 01626L105 (CUSIP Number) Lawrence M. Blatt, Ph.D. c/o Aligos Therapeutics, Inc. One Corporate Dr., 2nd Floor South San Francisco, CA 94080 (800) 466-6059 (Name, |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39617 Aligos Therapeutics, Inc. |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 2, 2023 |
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) - Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and f |
|
| November 2, 2023 |
ALGS / Aligos Therapeutics Inc / Deep Track Capital, LP Passive Investment SC 13G 1 deeptrack-algs102323.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 01626L105 (CUSIP Number) October 23, 2023 (Date of Event Which Requires Filing of this Statement) Check the |
|
| October 25, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 23, 2023 (the “Effective Date”), among Aligos Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each a “Purchaser” and collectively the “Purchasers”). WHEREAS, the Company and the Purchasers are executing and |
|
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2023 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commiss |
|
| October 25, 2023 |
Exhibit 4.1 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE SECURITIES REPRESENTED HEREBY MAY NOT BE OFFERED, SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER APPLICABLE SECURITIES LAWS UNL |
|
| October 25, 2023 |
Exhibit 4.2 THE SECURITIES REPRESENTED BY THIS CERTIFICATE AND THE UNDERLYING SECURITIES THAT MAY BE ISSUED UPON EXERCISE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE SECURITIES REPRESENTED HEREBY MAY NOT BE OFFERED, SOLD OR TRANSFER |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commiss |
|
| September 7, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commis |
|
| August 3, 2023 |
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) - Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39617 Aligos Therapeutics, Inc. |
|
| August 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commission |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commission |
|
| June 2, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| May 4, 2023 |
Non-Employee Director Compensation Policy Exhibit 4.3 ALIGOS THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (As Amended Effective: April 5, 2023) This Aligos Therapeutics, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2020 Incentive Award Plan (the “Plan”) and has been amended as of April 5, 2023 (the “Effective Date”). Capitalized terms not otherwise d |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39617 Aligos Therapeutics, Inc. |
|
| May 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 4, 2023 |
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results SOUTH SAN FRANCISCO, Calif., May 04, 2023 (GLOBE NEWSWIRE) - Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and fi |
|
| April 28, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 28, 2023 |
DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39617 Aligos Therape |
|
| March 9, 2023 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Aligos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 |
|
| March 9, 2023 |
Exhibit 21.1 List of Significant Subsidiaries of Aligos Therapeutics, Inc. Name Jurisdiction of Incorporation or Organization Aligos Belgium BV Belgium Aligos Australia Pty LTD Australia Aligos Therapeutics (Shanghai) Co. Ltd. China |
|
| March 9, 2023 |
Power of Attorney. Reference is made to the signature page to the Registration Statement. S-8 As filed with the Securities and Exchange Commission on March 9, 2023 Registration No. |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 9, 2023 |
EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results SOUTH SAN FRANCISCO, Calif., March 09, 2023 (GLOBE NEWSWIRE) - Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent busines |
|
| February 14, 2023 |
ALGS / Aligos Therapeutics Inc / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 algs28230sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 01626L105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check |
|
| February 14, 2023 |
SC 13G/A 1 p23-0181sc13ga.htm ALIGOS THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 01626L105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statem |
|
| February 13, 2023 |
ALGS / Aligos Therapeutics Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 01626L105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 8, 2023 |
ALGS / Aligos Therapeutics Inc / BLATT LAWRENCE - SC 13G/A Passive Investment SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Titl |
|
| December 27, 2022 |
ALGS / Aligos Therapeutics Inc / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 27, 2022 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Aligos Therapeutics, Inc. and further agree to the filing |
|
| December 22, 2022 |
CORRESP 1 filename1.htm 140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES Austin Milan Beijing Munich Boston New York Brussels Orange County Century City Paris December 22, 2022 Chicago Riyadh Dubai San Diego VIA EDGAR Düsseldorf San Francisco Frankfurt Seoul United States Securities and Exchange Commission Hamburg Shanghai D |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39617 Aligos Therapeutics, Inc. |
|
| November 2, 2022 |
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) - Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and f |
|
| November 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 4, 2022 |
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) - Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39617 Aligos Therapeutics, Inc. |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 27, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2022 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commission |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39617 Aligos Therapeutics, Inc. |
|
| May 4, 2022 |
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) - Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and fi |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 29, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2022 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commissio |
|
| March 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2022 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commissio |
|
| March 10, 2022 |
As filed with the Securities and Exchange Commission on March 10, 2022 As filed with the Securities and Exchange Commission on March 10, 2022 Registration No. |
|
| March 10, 2022 |
Exhibit 10.16 LEASE AGREEMENT THIS LEASE AGREEMENT (this ?Lease?) is made this 9th day of December, 2021, between 601 & 651 GATEWAY CENTER LP, a Delaware limited partnership (?Landlord?), and ALIGOS THERAPEUTICS, INC., a Delaware corporation (?Tenant?). Building: 601 Gateway Boulevard, South San Francisco, California 94080 Premises: That portion of the Building, commonly known as Suite 900, contai |
|
| March 10, 2022 |
Exhibit 21.1 List of Significant Subsidiaries of Aligos Therapeutics, Inc. Name Jurisdiction of Incorporation or Organization Aligos Belgium BV Belgium Aligos Australia Pty LTD Australia Aligos Therapeutics (Shanghai) Co. Ltd. China |
|
| March 10, 2022 |
EXHIBIT 99.1 Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1b ASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated ? 1st cohort fully enrolled siRNA (ALG-125755) progressing on track through Phase 1 enabling nonclinical studies T |
|
| March 10, 2022 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Aligos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39617 Aligos Therape |
|
| March 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 14, 2022 |
SC 13G/A 1 p22-0160sc13ga.htm ALIGOS THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 01626L105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statem |
|
| February 14, 2022 |
ALGS / Aligos Therapeutics Inc / BAKER BROS. ADVISORS LP - SCHEDULE 13G Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
ALGS / Aligos Therapeutics Inc / Logos Global Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 01626L105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 14, 2022 |
ALGS / Aligos Therapeutics Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 01626L105 (CUSIP Number) February 4, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 01626L105 (CUSIP Number) January 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 10, 2022 |
ALGS / Aligos Therapeutics Inc / BLATT LAWRENCE - SC 13G/A Passive Investment United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Clas |
|
| February 10, 2022 |
ALGS / Aligos Therapeutics Inc / Beigelman Leonid - SC 13G/A Passive Investment United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Secur |
|
| February 4, 2022 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 01626L105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 01626L105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| January 31, 2022 |
ALGS / Aligos Therapeutics Inc / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 01626L 105 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy t |
|
| January 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2022 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commissi |
|
| November 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2021 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commis |
|
| November 17, 2021 |
Aligos Therapeutics, Inc. One Corporate Dr., 2nd Floor South San Francisco, CA 94080 CORRESP 1 filename1.htm Aligos Therapeutics, Inc. One Corporate Dr., 2nd Floor South San Francisco, CA 94080 November 17, 2021 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Michael Davis Re: Aligos Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-260774) Ladi |
|
| November 4, 2021 |
EX-1.2 2 d250018dex12.htm EX-1.2 Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM November 4, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Aligos Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agen |
|
| November 4, 2021 |
EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2021 Financial Results Dosing of ALG-020572 (ASO) in healthy volunteers underway Enrollment in first 2 STOPS cohorts (120, 200 mg) complete; enrollment in 3rd cohort (400 mg) underway Clinical trial application (CTA) filed for 1st NASH drug candidate, ALG-055009, a THR-beta agonist SOUTH SAN FRANCISCO, Calif., Nov. |
|
| November 4, 2021 |
As filed with the Securities and Exchange Commission on November 4, 2021 Table of Contents As filed with the Securities and Exchange Commission on November 4, 2021 Registration No. |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 4, 2021 |
Exhibit 4.4 ALIGOS THERAPEUTICS, INC. INDENTURE Dated as of , 20 [], as Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Est |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39617 Aligos Therapeutics, Inc. |
|
| August 13, 2021 |
ALGS / Aligos Therapeutics Inc / Logos Global Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 01626L105 (CUSIP Number) August 3, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| August 5, 2021 |
Exhibit 10.1 CONFIDENTIAL CONSULTING AGREEMENT This CONSULTING Agreement is made and entered into as of June 17, 2021 (the ?Effective Date?) by and between Aligos Therapeutics, Inc., a Delaware corporation having a principal place of business at 1 Corporate Drive, 2nd Floor, South San Francisco, CA 94080 (?Aligos?) and Kathleen Sereda Glaub, an individual with an address of 1050 Lee Avenue, San Le |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 5, 2021 Aligos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39617 82-4724808 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39617 Aligos Therapeutics, Inc. |
|
| August 5, 2021 |
EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2021 Financial Results Raised $83.6 million in gross proceeds from common stock offering STOPS? and CAM programs: initial data presented at conferences, dosing in 2nd CHB cohorts ongoing Clinical trial application filed for 3rd CHB drug candidate ALG-0202572 (antisense oligonucleotide) ? dosing in HVs anticipated |
|
| July 1, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-257466 4,400,000 shares Common stock We are offering 4,400,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol ?ALGS.? The last reported sale price of our common stock on the Nasdaq Global Select Market on June 30, 2021 was $20.39 per share. We are an ?emerging growth |
|
| June 28, 2021 |
As filed with the Securities and Exchange Commission on June 28, 2021. S-1 1 d166948ds1.htm S-1 Table of Contents As filed with the Securities and Exchange Commission on June 28, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incor |
|
| June 28, 2021 |
Consulting Agreement by and between Aligos Therapeutics, Inc. and Kathy Glaub, dated June 17, 2021. Exhibit 10.15 CONSULTING AGREEMENT This CONSULTING AGREEMENT is made and entered into as of June 17, 2021 (the ?Effective Date?) by and between ALIGOS THERAPEUTICS, INC., a Delaware corporation having a principal place of business at 1 Corporate Drive, 2nd Floor, South San Francisco, CA 94080 (?Aligos?) and Kathleen Sereda Glaub, an individual with an address of 1050 Lee Avenue, San Leandro, CA 94 |
|
| June 28, 2021 |
Aligos Therapeutics, Inc. One Corporate Dr., 2nd Floor South San Francisco, CA 94080 Aligos Therapeutics, Inc. One Corporate Dr., 2nd Floor South San Francisco, CA 94080 June 28, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Laura Crotty Re: Aligos Therapeutics, Inc. Registration Statement on Form S-1 (Registration No. 333-257466) Ladies and |
|
| June 28, 2021 |
J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 Jefferies LLC 520 Madison Avenue New York, NY 10022 Piper Sandler & Co. 800 Nicollet Mall Minneapolis, MN 55402 June 28, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street, N.E. Washington, D.C. 20549 Attention: Laura Crotty Re: Aligos Therapeutics, Inc |
|
| June 28, 2021 |
Form of Underwriting Agreement. EX-1.1 2 d166948dex11.htm EX-1.1 Exhibit 1.1 UNDERWRITING AGREEMENT Aligos Therapeutics, Inc. [•] Shares of Common Stock , 2021 J.P. MORGAN SECURITIES LLC JEFFERIES LLC PIPER SANDLER & CO. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 |
|
| June 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2021 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commiss |
|
| June 24, 2021 |
Submission of Matters to a Vote of Security Holders 8-K 1 d123494d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of i |
|
| June 21, 2021 |
ALGS / Aligos Therapeutics Inc / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 01626L 105 (CUSIP Number) Peter Haahr Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. S |
|
| June 21, 2021 |
ALGS / Aligos Therapeutics Inc / Versant Venture Capital VI, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 01626L 10 5 (CUSIP Number) Versant Ve |
|
| June 4, 2021 |
Table of Contents CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. PURSUANT TO 17 C.F.R. Section 200.83 Confidential draft submitted to the Securities and Exchange Commission on June 4, 2021. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information contained herein remains confidential. Registration No. 333- UNITED S |
|
| May 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 10, 2021 Aligos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39617 82-4724808 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 10, 2021 |
Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the ?Agreement?) is entered into effective as of February 10, 2021 (the ?Effective Date?), by and between Aligos Therapeutics, Inc., a Delaware corporation (the ?Company?) and Leonid Beigelman, Ph.D. (the ?Executive?). A.The Company and the Executive are currently parties to that certain Employme |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39617 Aligos Therapeutics, Inc. |
|
| May 10, 2021 |
EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and First Quarter 2021 Financial Results Advancement of Aligos? drug candidates continues to be on track SOUTH SAN FRANCISCO, Calif., May 10, 2021 (GLOBE NEWSWIRE) - Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral an |
|
| May 10, 2021 |
DocuSign Envelope ID: 2DDB78FC-B0D7-40D1-AF5A-3F060FD066DF Exhibit 10.3 ALIGOS THERAPEUTICS, INC. May 14, 2019 Julian Symons 7 Azalea Lane San Carlos, CA 94070 RE: Confirmatory Employment Letter Dear Julian: This letter agreement (?Agreement?) is entered into between Julian Symons (?you?) and Aligos Therapeutics, Inc. (the ?Company? or ?we?), effective as of October 16, 2018 (the ?Effective Date?) |
|
| May 10, 2021 |
Form of Change in Control and Severance Agreement. Exhibit10.4 ALIGOS THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the ?Agreement?) is made and entered into by and between [] (?Executive?) and Aligos Therapeutics, Inc. (the ?Company?), effective as of December 1, 2020 (the ?Effective Date?). Background A.The Board of Directors of the Company (the ?Board?) recognizes that the possibili |
|
| May 10, 2021 |
Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the ?Agreement?) is entered into effective as of February 10, 2021 (the ?Effective Date?), by and between Aligos Therapeutics, Inc., a Delaware corporation (the ?Company?) and Lawrence M. Blatt, Ph.D. (the ?Executive?). A.The Company and the Executive are currently parties to that certain Employm |
|
| May 3, 2021 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 01626L 10 5 (CUSIP Number) V |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 27, 2021 |
DEF 14A 1 d65632ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Comm |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2021 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Commissio |
|
| March 23, 2021 |
Exhibit 4.3 Description of Capital Stock The following summary describes the capital stock of Aligos Therapeutics, Inc. (the ?Company,? ?we,? ?us? and ?our?) and the material provisions of our amended and restated certificate of incorporation and our amended and restated bylaws, the amended and restated investors? rights agreement to which we and certain of our stockholders are parties and of the |
|
| March 23, 2021 |
EXHIBIT 99.1 Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights - Advanced ALG-010133 and ALG-000184 into the clinic - both expected to generate safety and antiviral activity data in Chronic Hepatitis B (CHB) patients in 2021 - Listed on NASDAQ Global Select Market under the symbol ALGS and raised $167.2 million in gross proceeds from the |
|
| March 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39617 Aligos Therapeu |
|
| March 23, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 23, 2021 Aligos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39617 82-4724808 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 23, 2021 |
As filed with the Securities and Exchange Commission on March 23, 2021 Registration No. |
|
| February 16, 2021 |
SC 13G 1 tm216688d6sc13g.htm SC 13G CUSIP No. 01626L105 SCHEDULE 13G Page 1 of 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value, $0.0001 per share (Title of Class of Securities) 01626L105 (CUSIP Number) December 31, 2020 (Date of Event W |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 01626L105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursua |
|
| February 11, 2021 |
SC 13G United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.)* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of |
|
| February 11, 2021 |
SC 13G United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title o |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 01626L105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| November 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39617 Aligos Therapeutics, Inc. |
|
| October 30, 2020 |
EX-99.1 Exhibit 1 Joint Filing Agreement The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Aligos Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D. October 30, 2020 Versant Venture Capital VI, L.P. By: Versant Ventures VI GP, L.P. Its: Gen |
|
| October 30, 2020 |
ALGS / Aligos Therapeutics, Inc. / Versant Venture Capital VI, L.P. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 01626L 10 5 (CUSIP Number) Vers |
|
| October 28, 2020 |
ALGS / Aligos Therapeutics, Inc. / Vivo Capital VIII, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 01626L105 (CUSIP Number) October 20, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| October 22, 2020 |
ALGS / Aligos Therapeutics, Inc. / Novo Holdings A/S - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 01626L 105 (CUSIP Number) Peter Haahr Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayn |
|
| October 22, 2020 |
EX-99.1 Exhibit 99.1 FORM OF LOCK-UP AGREEMENT September , 2020 J.P. MORGAN SECURITIES LLC JEFFERIES LLC PIPER SANDLER & CO. As Representatives of the several Underwriters listed in Schedule 1 to the Underwriting Agreement referred to below c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o Jefferies LLC 520 Madison Avenue New York, NY 10022 c/o Piper Sandler & Co. 800 Nicoll |
|
| October 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aligos Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) October 12, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| October 20, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2020 Aligos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39617 82-4724808 (State or other jurisdiction of incorporation) (Com |
|
| October 20, 2020 |
S-8 As filed with the Securities and Exchange Commission on October 20, 2020 Registration No. |
|
| October 20, 2020 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ALIGOS THERAPEUTICS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROC |
|
| October 20, 2020 |
Amended and Restated Certificate of Incorporation. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ALIGOS THERAPEUTICS, INC. Aligos Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is Aligos Therapeutics, Inc. The Corporation’s original Certificate of Incorporation was filed with the Secretary of State of the |
|
| October 19, 2020 |
10,000,000 shares Common stock J.P. Morgan Jefferies Piper Sandler Cantor 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-249077 Prospectus 10,000,000 shares Common stock This is the initial public offering of shares of common stock of Aligos Therapeutics, Inc. We are selling 10,000,000 shares of our common stock. The initial public offering price is $15.00 per share. Prior to this offering, there has been no public market for our common st |
